PRTA
Prothena Corporation plcNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$585.16M
P/E Ratio
—
EPS
$-4.53
Beta
-0.33
52W High
$11.69
52W Low
$4.32
50-Day MA
$9.75
200-Day MA
$9.28
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
12.64
PEG Ratio
0.80
About Prothena Corporation plc
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is headquartered in Dublin, Ireland.
Fundamentals
| Revenue (TTM) | $9.68M |
| Gross Profit (TTM) | $-125.17M |
| EBITDA | $-183.66M |
| Operating Margin | -129576.00% |
| Return on Equity | -63.60% |
| Return on Assets | -26.40% |
| Revenue/Share (TTM) | $0.18 |
| Book Value | $5.21 |
| Price-to-Book | 2.21 |
| Price-to-Sales (TTM) | 60.43 |
| EV/Revenue | 33.09 |
| EV/EBITDA | -3.58 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.00% |
| Shares Outstanding | $53.83M |
| Float | $39.65M |
| % Insiders | 19.32% |
| % Institutions | 89.17% |
Historical Volatility
HV 10-Day
52.28%
HV 20-Day
43.29%
HV 30-Day
46.04%
HV 60-Day
45.51%
HV Rank
31.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($21.00 target)
2
Strong Buy2
Buy2
Hold1
Strong SellData last updated: 4/30/2026